|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Bayer's_dermatology_portfolio_(2018)
|
|
gptkbp:businessModel
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Catherine_Mazzacco
|
|
gptkbp:country
|
gptkb:Denmark
|
|
gptkbp:focusArea
|
rare diseases
skin diseases
thrombosis treatment
|
|
gptkbp:founded
|
1908
|
|
gptkbp:founder
|
gptkb:August_Kongsted
Anton Antons
|
|
gptkbp:headquarters_location
|
gptkb:Ballerup,_Denmark
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Leo Pharma
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:logo
|
Leo Pharma logo.svg
|
|
gptkbp:notableProduct
|
gptkb:Adtralza
gptkb:Daivobet
gptkb:Enstilar
gptkb:Fucidin
gptkb:Heparin
|
|
gptkbp:numberOfEmployees
|
~6000
|
|
gptkbp:operatesIn
|
global
|
|
gptkbp:ownedBy
|
gptkb:LEO_Foundation
|
|
gptkbp:parentOrganization
|
gptkb:LEO_Foundation
|
|
gptkbp:products
|
over-the-counter drugs
prescription drugs
|
|
gptkbp:research_and_development
|
yes
|
|
gptkbp:revenue
|
~EUR 1.3 billion (2022)
|
|
gptkbp:specializesIn
|
dermatology
thrombosis
|
|
gptkbp:stockExchange
|
not publicly listed
|
|
gptkbp:subsidiary
|
gptkb:LEO_Pharma_Inc._(USA)
|
|
gptkbp:website
|
https://www.leo-pharma.com/
|
|
gptkbp:bfsParent
|
gptkb:Ballerup,_Denmark
gptkb:tinzaparin
|
|
gptkbp:bfsLayer
|
7
|